Cardiosense wins FDA De Novo for noninvasive PCWP software: full analysis

Cardiosense has received FDA De Novo classification for its PCWP Analysis Software, giving the company a first-in-class regulatory win for software designed to estimate pulmonary capillary wedge pressure without an invasive catheter or implant. The company said the software, used with its CardioTag wearable chest sensor, is intended to help clinicians detect worsening congestion earlier in adults with heart failure with reduced ejection fraction. The FDA’s De Novo database lists the product as DEN250057, with a decision date of May 22, 2026. (accessdata.fda.gov)

The decision builds on Cardiosense’s earlier regulatory progress. In July 2025, the FDA cleared the CardioTag wearable sensor through the 510(k) pathway, setting up the hardware side of the platform. Cardiosense had also previously received Breakthrough Device designation for its algorithm, and has been positioning the technology as a way to bring pressure-guided heart failure management beyond invasive monitoring and into point-of-care or outpatient settings. (businesswire.com)

At the center of the story is PCWP, a hemodynamic measure tied to cardiac filling pressure and fluid overload. In clinical practice, that matters because congestion often worsens before symptoms become obvious. Cardiosense says its software uses AI to generate a noninvasive estimate from signals collected by the chest-worn CardioTag sensor. According to the company, the indication covers adult patients with HFrEF, defined here as LVEF of 40% or less, and NYHA class II to IV symptoms. The company also said both the CardioTag device and the PCWP Analysis Software are now authorized to market as class II devices in the US. (businesswire.com)

The clinical rationale has been building for several years. Cardiosense’s SEISMIC-HF I study was presented as late-breaking science at the American Heart Association’s 2024 Scientific Sessions, and the company later said the findings were published in JACC: Heart Failure. The journal abstract describes a prospective, multicenter study in 310 patients with HFrEF recruited in inpatient and outpatient settings to develop a generalizable machine-learning algorithm for PCWP estimation. Cardiosense has said the results showed accuracy comparable to implanted pressure sensors. (jacc.org)

Industry coverage has framed the De Novo decision as more than a single-company milestone. Medical Economics noted that the authorization establishes a new regulatory category for AI-based, noninvasive PCWP estimation intended for low- to moderate-risk use without a predicate device. In Cardiosense’s announcement, CEO Eric Meizlish called the decision a “transformative milestone,” while co-founder and chief scientific officer Omer Inan said the technology reflects years of multidisciplinary research and engineering. (medicaleconomics.com)

Why it matters: For veterinary professionals, the direct clinical application is limited today because this is a human FDA authorization. But the broader signal is important. Regulators are showing a willingness to create new pathways for wearable-plus-software systems that estimate meaningful physiologic parameters noninvasively. That has implications for how veterinary medicine may eventually see similar approaches emerge in cardiology, remote monitoring, and chronic disease management, especially as pet parent demand grows for earlier detection and less invasive care. It’s also a reminder that AI in monitoring is increasingly being judged not just on novelty, but on whether it can produce an actionable metric tied to treatment decisions. (medicaleconomics.com)

There are still important open questions. De Novo classification is a regulatory milestone, but adoption will depend on how clinicians use the tool in practice, what evidence emerges on outcomes, reimbursement, and how the FDA frames special controls in the eventual decision summary. Cardiosense has also said it plans to introduce additional algorithms for heart failure detection and for heart failure with preserved ejection fraction, so the next phase will likely focus on label expansion, validation studies, and commercial uptake. (fda.gov)